While GHK-Cu remains a frontrunner, exploring these additional peptides widens the scope of available solutions for individuals seeking to improve their hair health
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Yu, S., Rao, S., and Reddy, J
Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation
Many peptides follow a cycling protocol, which means you take peptides for some period (on cycle) and then take a break (off-cycle)